Trial Profile

Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Fludarabine (Primary) ; Inotuzumab ozogamicin (Primary) ; Melphalan (Primary) ; Rituximab (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Filgrastim; Methotrexate; Ponatinib
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Richter's syndrome
Focus Adverse reactions

04 Feb 2025 Planned End Date changed from 31 Mar 2025 to 31 Mar 2027.
04 Feb 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Mar 2027.
29 Jan 2024 Eligibility criteria amended from 18-70 years to 12-70 years. Study interventions amended. Biological: Anti-Thymocyte Globulin and drug Methotrexate removed from study protocol.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com